GRANULOMATOUS MENINGOENCEPHALITIS (GME)
Granulomatous Meningoencephalitis (GME)
THE CLINICAL PICTURE OF GME
The classical patient is a middle-aged small breed dog of either gender. What sort of neurologic signs are seen depend totally on what area of the nervous system is involved. Seizures, neck pain, drunken gait, walking in circles, blindness, listlessness, tilted head, facial abnormalities, and weakness can be seen. This does not leave out much in the way of neurologic symptoms.
TYPES OF GME
There are three types of GME: focal (limited to one location in the nervous system); disseminated or multifocal (involving many locations in the nervous system); and ophthalmic (involving the optic nerve/eye). A patient may have more than one type. The disseminated form is the most common.
The focal type of GME typically has a slower onset (3-6 months) while the disseminated form is more rapid (2-6 months). Obviously, the disseminated form has a larger variety of signs within the same patient. The ophthalmic form most commonly shows up as sudden, generally permanent blindness. It can affect one or both eyes. The disseminated form has a particularly poor prognosis; in one study the median survival time after diagnosis was 8 days, a testament to the rapid progression and severity of this condition.
MAKING THE DIAGNOSIS
Diagnostic image courtesy of animalmr.com
A basic blood panel/urinalysis is important for any sick pet (not to mention for the monitoring of healthy elderly pets). A basic blood panel and urinalysis form the foundation of evaluation and determination of what medication can be used, and what other systems must be considered.
Tapping of the cerebrospinal fluid (spinal tap) is very helpful in the diagnosis of GME. General anesthesia is required to tap fluid from the nervous system and the procedure is not entirely without risk. Still, the cells of GME should be findable in the fluid if they are present in the brain. Prior administration of cortisone-type medication may reduce the cells found in the tap and must be considered in the interpretation of the tap.
This kind of testing also helps in ruling out other conditions that might present similarly:
Since the treatment for GME involves immune-suppression, the CSF tap also serves to rule out infectious diseases which would be made substantially worse with suppression of the immune system.
MRI (magnetic resonance imaging) is able to image the brain in such detail that it is considered nearly a confirming test for GME. CT (CAT scanning) is not as definitive. If the diagnosis is felt to still be questionable after spinal tap, MRI should be considered despite expense.
The only way to confirm GME with 100% certainty is by biopsy though, obviously, diagnostics do not get any more invasive than brain surgery. For this reason, confirmation is frequently post-mortem.
Immune-suppression with corticosteroids (such as prednisone) remains the center of therapy for GME. Once the disease is controlled, one may begin to gradually drop the steroid dose until the minimum dose required to control the disease is reached. This process can be expected to require 4 months or so. It is unusual for a patient to be able to fully discontinue medication but at least stronger immune-suppressive agents are rarely required.
A chemotherapy agent called procarbazine has been combined with prednisone to improve the legnth of GME remission. A study by Dr. Joan Coates et al. from the University of Missouri was published in the January/February 2007 issue of the Journal of the American College of Veterinary Internal Medicine. In this study, 21 dogs with GME were treated with both procarbazine and prednisone and outcomes compared to those of 11 dogs who were found to have GME on post-mortem and had received no treatment. Median survival time of the treated dogs was 14 months compared to less than one month for dogs receiving no treatment. Of the 21 dogs, 17 were able to reduce their steroid use or even discontinue it. Of the 21 dogs, 7 developed bone marrow suppression side effects and 3 dogs developed serious gastrointestinal side effects (hemorrhagic gastroenteritis). Although researchers concluded that procarbazine and prednisone was a more effective combination than prednisone alone, they did not actually include a group of dogs treated with prednisone alone in this study.
A new drug called leflunomide has been released to treat immune-mediated diseases of a type that includes GME. This is a relatively expensive treatment, which has limited use but it remains as a possible alternative to corticosteroid use for dogs that do not tolerate corticosteroid side effects.
Other drugs that show promise but have only been tested in a small number of patients include cyclosporine, an immunomodulator used to inhibit organ transplant rejection, and cytosine arabinoside, another chemotherapy agent that can be combined with prednisone. Cytosine arabinoside is given as a series of 4 injections over 2 days and then every 3-6 weeks while cyclosporine is given orally usually twice daily. Lomustine, another agent of chemotherapy, has also been used for GME. It is given orally every 6 weeks in combination with steroids. Results with any of these agents have been encouraging. For example, the GME protocol used at Cornell University (oral prednisone, oral cyclosporine, and cytosine arabinoside infusions) has led to remission within 36 hours in the majority of patients and the average survival time is 2-3 years.
If the GME is focal or localized, radiotherapy may be helpful. Radiation of the head or face can lead to infarction (abnormal clotting), which can in turn lead to seizures for periods as long as 5 to 6 months after therapy. Cataracts and dry eye are common results of radiotherapy should the eyes be included in the field of radiation. That said, many cases of focal GME have enjoyed complete resolution after radiation.
If seizures have been a manifestation of GME, either disseminated or focal, medication will be used to control the seizures. Anti-seizure medication is the same regardless of the cause of the seizures so something specific for GME seizures is not needed. For a review of anti-seizure medication see the section on seizure disorders.
Ophthalmic GME also uses oral corticosteroids for therapy but may also employ topical ones. If glaucoma results from GME then therapy for this is necessary. Again, therapy for this result of GME is addressed in a standard way; no specific GME glaucoma therapy is needed.
Page last updated: 7/19/2016